<p>Tocilizumab is an interleukin-6 (IL-6) receptor antagonist indicated for treatment of:</p>

<ul>
	<li><strong>Rheumatoid Arthritis (RA)</strong>: Adult patients with moderately to severely active rheumatoid arthritis who have had an inadequate response to one or more Disease-Modifying Anti-Rheumatic Drugs (DMARDs).</li>
	<li><strong>Giant Cell Arteritis (GCA)</strong>:&nbsp;Adult patients with giant cell arteritis.</li>
	<li><strong>Systemic Sclerosis-Associated Interstitial Lung Disease (SSc-ILD)</strong>: Slowing the rate of decline in pulmonary function in adult patients with systemic sclerosis-associated interstitial lung disease (SSc-ILD)</li>
	<li><strong>Polyarticular Juvenile Idiopathic Arthritis (PJIA)</strong>: Patients 2 years of age and older with active polyarticular juvenile idiopathic arthritis.</li>
	<li><strong>Systemic Juvenile Idiopathic Arthritis (SJIA)</strong>: Patients 2 years of age and older with active systemic juvenile idiopathic arthritis.</li>
	<li><strong>Cytokine Release Syndrome (CRS)</strong>: Adults and pediatric patients 2 years of age and older with chimeric antigen receptor (CAR) T cell-induced severe or life-threatening cytokine release syndrome.</li>
</ul>